Health & Fitness
Health and Fitness
Health and Fitness
Thu, April 19, 2012Wed, April 18, 2012Tue, April 17, 2012Mon, April 16, 2012Sun, April 15, 2012Sat, April 14, 2012Fri, April 13, 2012Thu, April 12, 2012Wed, April 11, 2012Tue, April 10, 2012Mon, April 9, 2012Fri, April 6, 2012Thu, April 5, 2012Wed, April 4, 2012Tue, April 3, 2012Research on Mylan Inc. and Watson Pharmaceuticals Inc. - Generic Drug Makers Take to the Courts
Published in Health and Fitness on Thursday, April 12th 2012 at 5:20 GMT by Market Wire
April 12, 2012 08:15 ET
Research on Mylan Inc. and Watson Pharmaceuticals Inc. - Generic Drug Makers Take to the Courts
JOHANNESBURG, SOUTH AFRICA--(Marketwire - Apr 12, 2012) - [ www.stockcall.com/ ] offers investors comprehensive research on the Drugs - Generic industry and has completed analytical research on Mylan Inc. (
A series of legal battles could shape both the short- and long-term for generic drug makers, as battles over exclusivity rights and patent claims could send companies in different directions.
[ www.stockcall.com/ ] is an online platform where investors doing their due-diligence on the Drugs - Generic industry can have easy and free access to our analyst research and opinions on Mylan Inc. and Watson Pharmaceuticals Inc.; investors and shareholders of these companies can simply register for a complimentary membership at [ https://stockcall.com/development/stockcall/page.php?name=register.html ].
One company that has been working hard as of late is Watson Pharmaceuticals Inc. The company has an Abbreviated New Drug Application for a generic version of Sanctura XR. The drug is currently pending with the FDA but could send revenues higher if approved, considering the impressive U.S. sales of the drug in the past year. Investors can register for free to access the research reports on Watson Pharmaceuticals Inc. at [ www.stockcall.com/WPI120412.pdf ].
Exclusivity rights have also been a point of contention for generic drug makers. Mylan Inc. is suing the FDA to reverse a decision that granted 180 days of exclusivity to rival Teva Pharmaceuticals for the generic type of drug Provigil. Mylan is pushing for a quick decision and hopes to market the drug shortly after. The case will be well worth tracking for Mylan investors. Investors can register for free to access the research reports on Mylan Inc. at [ www.stockcall.com/MYL120412.pdf ].
Register now at [ https://stockcall.com/development/stockcall/page.php?name=register.html ] to have free access to our reports on the Drugs - Generic industry.
About StockCall.com
StockCall.com is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines.
